George Lundberg, MD Editor in Chief at Cancer Commons

  •   George Lundberg, MD

    The ASCO Post reports on the U.S. Food And Drug Administration (FDA)’s recent approval of two new treatments for advanced, unresectable squamous cell carcinoma of the esophagus.

    .

  •   George Lundberg, MD

    This article from the International Kidney Cancer Coalition (IKCC) outlines updates on treatment options for renal cell carcinoma as presented at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium.

    .

  •   George Lundberg, MD

    This article from the National Cancer Institute’s Center for Cancer Research outlines new clinical trial results showing that combining the drugs cabozantinib and nivolumab doubled progression-free survival for people with advanced renal cell carcinoma compared to giving cabozantinib alone.

    .

  •   George Lundberg, MD

    This review article in the academic research journal Biomarker Research discusses how combining immunotherapy and targeted therapies provides new hope for people with hepatocellular carcinoma.

    .

  •   George Lundberg, MD

    In this article for Cancer Therapy Advisor, Dr. Shaalan Beg shares updates from the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium on treatments for advanced hepatocellular carcinoma.

    .

  •   George Lundberg, MD

    As reported by The ASCO Post, the drug adagrasib has shown some promising results in a clinical trial for people with advanced non-small cell lung cancer (NSCLC) with a KRAS-g12c mutation whose cancer progressed after prior treatment. The U.S. Food and Drug Administration (FDA) allows adagrasib to be given to people whose cancer has a KRAS-g12c mutation through expanded access.

    .

  •   George Lundberg, MD

    The most common brain tumors are other types of cancer that have spread (or “metastasized”) to the brain from a primary site elsewhere in the body. And, the genomic makeup of the brain metastases may not be the same as the primary cancer. An article from The ASCO Post discusses what this means for treatment.

    .

  •   George Lundberg, MD

    According to MedPage Today, the addition of the drug relatlimab to treatment with nivolumab improved survival for people with advanced melanoma in a clinical trial.

    .

  •   George Lundberg, MD

    Cancer that spreads to the brain is very difficult to treat, especially because of the blood-brain barrier. This article from The ASCO Post describes one promising new treatment.

    .

  •   George Lundberg, MD

    Written for oncology healthcare professionals, this article from the American Journal of Hematology covers the best new therapies for chronic myelomonocytic leukemia in 2022.

    .